Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

6 results
12:00 AM, Feb 03, 2014  |  BioCentury | Product Development

Spies graduate

NASDAQ:AMGN) Trebananib (AMG 386) Recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietin 1 (ANG1; ANGPT1) and angiopoietin 2
ANG2; ANGPT2) Entered Mar 2010; status undisclosed Amgen Inc. (NASDAQ:AMGN) Ganitumumab (AMG 479) Human mAb targeting …
12:00 AM, Oct 17, 2011  |  BioCentury | Product Development

Tremelimumab, take three

and IGF-2 ; MEDI-551 , an anti- CD19 mAb; and MEDI-3617 , a mAb against angiopoietin 2
ANG2 ). All are in Phase I testing for cancer. BMS has its own combination …
12:00 AM, Jun 21, 2010  |  BioCentury | Product Development

Targeting ovarian

a recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietin 1 ( ANG1 ; ANGPT1 ) and angiopoietin 2
ANG2 ; ANGPT2 ). ANG1 and ANG2 interact with tyrosine kinase receptor 2 (Tie2) to …
remodeling. ANG1 promotes vessel stabilization by increasing endothelial junctions and pericyte coverage of endothelial cells. ANG2
12:00 AM, Mar 22, 2010  |  BioCentury | Product Development

Spies plot revolution

related apoptosis-inducing ligand receptor 2 (TRAIL-R2) AMG 386 Amgen Inc. (NASDAQ:AMGN) Angiopoietin 1 (ANG1; ANGPT1); angiopoietin 2
ANG2; ANGPT2) Figitumumab Pfizer Inc. (NYSE:PFE) Insulin-like growth factor-1 receptor (IGF1R; CD221) Neratinib (HKI-272) Pfizer Inc …
12:00 AM, Feb 23, 2009  |  BioCentury | Product Development

Pipeline proliferation

against EGFR 1 (HER1) (ErbB1) Recombinant Fc-peptide fusion protein(peptibody) targeting angio- poietin 1 (Ang1) and Ang2
12:00 AM, Feb 23, 2009  |  BioCentury | Product Development

Amgen's cancer trove

sarcoma. AMG 386 is a peptibody (Fc-peptide fusion protein) that targets the angiopoietins Ang1 and Ang2
neovascularization via the Tie2 receptor in a pathway that is separate from VEGF. Amgen believes Ang1/Ang2